--- canonical_url: https://www.stockexpertai.com/earnings/rvty last_updated: 2026-05-09T16:30:29.815Z --- # Revvity, Inc. (RVTY) Q4 FY2026 Earnings Preview > This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-09T16:30:29.314Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $101.00 (▲ 2.18%) | fmp:quote | | Market Cap | $11.3B | fmp:profile | | 52w range | $81.22 – $118.30 | fmp:quote | | Earnings | Mon 27 Jul | fmp:earnings-history | | EPS estimate | $1.26 (+7% YoY) | fmp:earnings-estimate | | Revenue estimate | $710.6M | fmp:earnings-estimate | | Beat streak | 8/4 | fmp:earnings-history | | Rating | B (overall 3/5) | fmp:ratings | | Analyst median target | $106 (+5.0% upside) | fmp:price-target-consensus | | MoonshotScore | 46/100 | derived | | Council | 2/6 bullish | derived | | Munger verdict | Fairly Valued | derived | ## Revvity, Inc. — Q4 FY2026 Expectations Q4 consensus: revenue $710.6M^{[FMP est]}, EPS $1.26^{[FMP est]}. 8 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** B · **Stance:** HOLD · **Council:** 2/6 · **Moonshot:** 46 = MoonshotScore 46^{[9-pillar formula]} + Council 2/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (6 metrics) ### 1. Fy26 Organic Growth Guidance Revvity is now projecting organic growth of 3% to 4% for fiscal year 2026. > "As it pertains to our updated pro forma guidance for 2026, which now excludes the immunodiagnostics business in China, we are now looking for organic growth of 3% to 4%, adjusted operating margins of 28.4%, and adjusted earnings per share of $5.20 to $5.30, which includes a 20% reduction related to the planned divestiture, offset by $0.05 of benefit from improved operational execution throughout the year." > — Prahlad Singh, CEO, Expectation / Guide · Q1 FY2026 ### 2. Pro Forma Organic Growth Improvement Revvity expects its pro forma organic growth to improve by approximately 100 basis points due to the divestiture of the China immunodiagnostics business. > "We expect this change to improve our 2026 total company organic growth by approximately 100 basis points and enhance our operating margins by approximately 30 basis points." > — Prahlad Singh, CEO, Investor Focus · Q1 FY2026 ### 3. China Immunodiagnostics Divestiture Revvity has decided to divest its immunodiagnostics business in China to focus resources on areas with higher returns. > "Following an extensive review, we have decided to divest our immunodiagnostics business in China, which represented approximately 6% of total company revenue last year." > — Prahlad Singh, CEO, Risk Indicator · Q1 FY2026 ### 4. Ai Driven Demand For Lab Tools As AI generates more promising therapeutic hypothesis at an unprecedented rate, the downstream demand for laboratory tools, reagents, and instruments to validate these discoveries will grow substantially. > "As AI generates more promising therapeutic hypothesis at an unprecedented rate, the downstream demand for laboratory tools, reagents, and instruments to validate these discoveries will grow substantially." > — Prahlad Singh, CEO, Investor Focus · Q1 FY2026 ### 5. Signals Software Innovation Revvity's Signals software business introduced Xynthetica, its AI models as a service platform that serves as a secure marketplace, collecting computational capabilities to wet lab research. > "In our Signals software business, we introduced Xynthetica in December, our AI models as a service platform that serves as a secure marketplace, collecting computational capabilities to wet lab research." > — Prahlad Singh, CEO, Investor Focus · Q1 FY2026 ### 6. Pharma Biotech Spending Improvement Revvity saw a modestly improved pharma and biotech spending environment, which led to positive low single-digit year-over-year organic growth from these customers. > "We saw a modestly improved pharma and biotech spending environment in the first quarter, which led to positive low single-digit year-over-year organic growth from these customers." > — Prahlad Singh, CEO, Investor Focus · Q1 FY2026 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 0.0 | weak | Q1 vs Q2: growth negative (-1.3%, contraction) | | Gross Margin | 5.0 | medium | Q1: high margin (54.5%) | | Operating Leverage | 1.0 | weak | op margin average (10.7%) | | Cash Runway | 10.0 | strong | FCF very strong ($0.1B, 4.8× CapEx) | | R&D Intensity | 5.0 | medium | average R&D (7.6%) | | Price Momentum | 7.0 | strong | RSI 67.3 positive momentum, 50d above | | News Sentiment | 4.0 | medium | mixed (44% buy) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +5.0% | | Ken Griffin | bull | flow · 50d MA above | | Jim Simons | neutral | quant · RSI 67 | | Klarman | neutral | value · target upside +5.0% | | Buffett | neutral | quality · ROE score 2/5 | | Munger | neutral | valuation · target upside +5.0% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Fairly Valued - **Financial Health:** Moderate - **Margin of Safety:** Weak - **Interest Coverage:** Adequate - **ROIC vs WACC:** Tight **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 67.3 — yükselişte nötr — overbought sınırının altında, momentum pozitif - **50d MA:** $90 — hisse %12.2 üstünde — kısa vadeli destek - **200d MA:** $94 — hisse %7.0 üstünde — uzun vadeli destek - **Volume (10d):** +45% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q2 FY25 | $1.18 | $1.14 | BEAT | -0.6% | | Q3 FY25 | $1.18 | $1.14 | BEAT | -0.7% | | Q4 FY25 | $1.70 | $1.57 | BEAT | -5.6% | | Q1 FY26 | $1.06 | $1.02 | +3.9% EPS | +7.4% | Q1 (May 5, 2026): EPS $1.06 vs $1.02 est^[FMP], +3.9% beat. D+1 movement: +7.4%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q4 EPS > $1.26 + CapEx discipline** Threshold: EPS > $1.26^{[FMP est]}. Target: Break above median target $106^{[FMP target]}; high target $124^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $1.26 + CapEx < $19.8M** Threshold: EPS ≈ $1.26^{[FMP est]}, Q4 CapEx < $19.8M^[FMP]. Target: Consolidation in the band between current $101^[FMP] and median $106^[FMP]. ### Scenario C · Miss **EPS < $1.22 or CapEx ≥ $19.8M** Threshold: EPS < $1.22^{[FMP est×0.97]}. Target: Current $101 below SMA200 $94^[FMP], if rejection continues, $80^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q1: EPS $1.06 vs $1.02 beat^[FMP], stock +7.4% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q1 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26 ### CapEx shock Q1 CapEx $19.8M^{[FMP cashflow]}. Q1 op margin 10.7%^{[FMP op margin]} — this level in Q4 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $106 (+5.0% upside vs current $101) - **High / Low:** $124 / $95 - **Buy / Hold / Sell:** 7 / 9 / 0 - **Analyst count:** 4 (last quarter), 27 all-time ## Additional Transcript Insights ### 1. china_immunodiagnostics_divestiture **Claim:** Revvity has decided to divest its immunodiagnostics business in China to focus resources on areas with higher returns. **Evidence (transcript):** "Following an extensive review, we have decided to divest our immunodiagnostics business in China, which represented approximately 6% of total company revenue last year." **Numbers:** 6% ### 2. pro_forma_organic_growth_improvement **Claim:** Revvity expects its pro forma organic growth to improve by approximately 100 basis points due to the divestiture of the China immunodiagnostics business. **Evidence (transcript):** "We expect this change to improve our 2026 total company organic growth by approximately 100 basis points and enhance our operating margins by approximately 30 basis points." **Numbers:** 100, 30 ### 3. fy26_organic_growth_guidance **Claim:** Revvity is now projecting organic growth of 3% to 4% for fiscal year 2026. **Evidence (transcript):** "As it pertains to our updated pro forma guidance for 2026, which now excludes the immunodiagnostics business in China, we are now looking for organic growth of 3% to 4%, adjusted operating margins of 28.4%, and adjusted earnings per share of $5.20 to $5.30, which includes a 20% reduction related to the planned divestiture, offset by $0.05 of benefit from improved operational execution throughout the year." **Numbers:** 3%, 4%, 28.4%, 5.20, 5.30, 20%, 0.05 ### 4. pharma_biotech_spending_improvement **Claim:** Revvity saw a modestly improved pharma and biotech spending environment, which led to positive low single-digit year-over-year organic growth from these customers. **Evidence (transcript):** "We saw a modestly improved pharma and biotech spending environment in the first quarter, which led to positive low single-digit year-over-year organic growth from these customers." **Numbers:** — ### 5. signals_software_innovation **Claim:** Revvity's Signals software business introduced Xynthetica, its AI models as a service platform that serves as a secure marketplace, collecting computational capabilities to wet lab research. **Evidence (transcript):** "In our Signals software business, we introduced Xynthetica in December, our AI models as a service platform that serves as a secure marketplace, collecting computational capabilities to wet lab research." **Numbers:** — ### 6. ai_driven_demand_for_lab_tools **Claim:** As AI generates more promising therapeutic hypothesis at an unprecedented rate, the downstream demand for laboratory tools, reagents, and instruments to validate these discoveries will grow substantially. **Evidence (transcript):** "As AI generates more promising therapeutic hypothesis at an unprecedented rate, the downstream demand for laboratory tools, reagents, and instruments to validate these discoveries will grow substantially." **Numbers:** — --- *Data source: FMP (live query, 2026-05-09), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*